Found 9 results
Filters: Keyword is Mutation [Clear All Filters]
“Progranulin deficiency leads to reduced glucocerebrosidase activity.”, PLoS One, vol. 14, no. 7, p. e0212382, 2019.
, “Progress toward development of a proteostasis drug for myocilin-associated glaucoma.”, Future Med Chem, vol. 10, no. 12, pp. 1391-1393, 2018.
, “Ligands for glaucoma-associated myocilin discovered by a generic binding assay.”, ACS Chem Biol, vol. 9, no. 2, pp. 517-25, 2014.
, “Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human α-galactosidase a: pharmacological chaperoning efficacy on Fabry disease mutants.”, ACS Chem Biol, vol. 9, no. 7, pp. 1460-9, 2014.
, “The glaucoma-associated olfactomedin domain of myocilin is a novel calcium binding protein.”, J Biol Chem, vol. 287, no. 52, pp. 43370-7, 2012.
, “Glucose-regulated protein 94 triage of mutant myocilin through endoplasmic reticulum-associated degradation subverts a more efficient autophagic clearance mechanism.”, J Biol Chem, vol. 287, no. 48, pp. 40661-9, 2012.
, “New direction for glaucoma therapeutics: focus on the olfactomedin domain of myocilin.”, Future Med Chem, vol. 4, no. 17, pp. 2131-4, 2012.
, “Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-β-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease.”, Biochemistry, vol. 50, no. 49, pp. 10647-57, 2011.
, “The stability of myocilin olfactomedin domain variants provides new insight into glaucoma as a protein misfolding disorder.”, Biochemistry, vol. 50, no. 26, pp. 5824-33, 2011.
,